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cense.Abstract Aim of the work: The aim of the present study was to investigate the association of
serum osteoprotegerin (OPG) level with the presence of angiographically documented asymptom-
atic coronary artery disease (CAD) in patients with rheumatoid arthritis (RA) and to evaluate its
relationship with plasma thrombomodulin (TM), as a marker of endothelial dysfunction and with
carotid artery intima media thickness (IMT), as a marker of atherosclerosis.
Patients and methods: The study included 20 rheumatoid patients without CAD (negative results
on exercise ECG stress test) and other 20 rheumatoid patients with CAD (positive results on exer-
cise ECG stress test and conﬁrmed by coronary angiography). In addition, 20 age and sex matched
normal control subjects were studied. Serum OPG and plasma TM levels were measured and car-
otid artery IMT was determined., Mouwasat Hospital, 31411
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36 A.M. Alsalawy et al.Results: The study revealed that serum OPG levels were signiﬁcantly higher in rheumatoid
patients with and without CAD than in controls (P< 0.001, P< 0.01; respectively) and were pos-
itively correlated with age, duration of disease, Disease active score 28(DAS28), Erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP) and carotid IMT in rheumatoid patients with and
without CAD. Serum OPG level was correlated signiﬁcantly with plasma TM only in rheumatoid
patients with CAD (P< 0.001).
Conclusion: Osteoprotegerin is a clinically important molecule independently associated with the
presence of coronary artery disease and may be a good indicator of atherosclerotic vascular damage
and macroangiopathy in asymptomatic rheumatoid patients. Hence, measurement of serum OPG
merits further investigation as a simple test for improving early diagnosis of asymptomatic CAD
in rheumatoid patients.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
characterized by increased mortality largely attributable to
cardiovascular disease [1].
Articular bone erosions is a characteristic feature of RA [2]
and one of its skeletal complications as well as systemic
osteopenia that result in an increased risk of bone fractures
[3]. Previous studies investigating the pathogenic mechanisms
of bone destruction in animal models of arthritis have pro-
vided substantial evidence that the osteoclast is the cell type
primarily responsible for focal bone erosion, and its generation
and activity are dependent upon receptor activator of Nuclear
factor-kB ligand (RANKL) [4,5].
OPG is a newly identiﬁed glycoprotein, belonging to the
tumor necrosis factor receptor superfamily, originally discovered
as an inhibitor of bone resorption. This inhibition is mediated
through OPG’s binding and neutralization of RANKL which
is a strong inducer of ostoeclast differentiation [6]. Interestingly,
it has been demonstrated that OPG is produced by a variety of
tissues, including the cardiovascular system (heart, arteries,
and veins), lung, kidney, and immune tissues, as well as bone
[6], and is regulated by various cytokines and hormones [7].
Emerging evidence indicates that osteoporosis and athero-
sclerotic vascular diseases are commonly found together. Con-
ceptually, a shift of calcium from the skeleton toward the
arterial wall can account for both disorders, but the underlying
paracrine mechanisms that operate in bone metabolism and
vascular homeostasis have not been deﬁned. Mouse genetics
may have unraveled the potential molecular link between oste-
oporosis and arterial calciﬁcation [8].
It has been shown that OPG-deﬁcient mice develop both
severe osteoporosis and medial calciﬁcation of the aorta and
renal arteries [9,10], and they were completely prevented by
restoration of the gene [11]. Thus, OPG has been proposed
as the link between osteoporosis and atherosclerosis. Further-
more, OPG seems to play an important part in preventing ero-
sions and osteoporosis in patients with RA [12]. While in
postmenopausal women, a single subcutaneous injection of
OPG rapidly reduced biochemical markers of bone resorption
[13]. A strong association between serum levels of OPG and
severity of coronary artery disease was observed in former
research [14]. Moreover, OPG level was found to be higher
in rheumatoid arthritis patients [15].
The aim of the present study was therefore to investigate
the association of OPG serum level with the presence ofangiographically documented asymptomatic CAD in RA pa-
tients and to evaluate its relationship with plasma TM as a
marker of endothelial dysfunction and with carotid artery
IMT as a marker of atherosclerosis.
2. Patients and methods
75 RA patients were collected to be enrolled within the current
study with deﬁnite RA, diagnosed according to the 2010 Amer-
ican College of Rheumatology (ACR) /European League
against Rheumatism (EULAR) classiﬁcation criteria for rheu-
matoid arthritis [16]. They were selected from those attending
the rheumatology, internal medicine clinics of Mouwasat
Hospital, Dammam, KSA. The patients had no history or
symptoms of coronary events and with normal resting
electrocardiography (ECG). RA patients were further recruited
according to the presence or absence of CAD(28 patients with-
out CAD, 21 patients with CAD, and 26 patients refused to
continue with the procedures of the research so they had been
excluded from the study) into two groups, Group I: included
20 rheumatoid patients (selected from originally 28 patients)
without CAD (negative results on exercise ECG stress test)
and Group II: included 20 rheumatoid patients (selected from
originally 21 patients) with CAD (positive results on exercise
ECG stress test and conﬁrmed by coronary angiography).
A written consent was taken from all enrolled patients
before starting any of the procedures of the research.
Patients suffering from uncontrolled hypertension, acute
infection, renal disease (serum creatinine > 2.0 mg/dl), diabe-
tes mellitus, or malignancies were excluded from the study.
Twenty volunteers of matched age (50.2 ± 3.3) and sex (14
females and 6 males), normotensive, 12 were smokers (60%),
with vertebral Bone Mineral Density (BMD) T-score was
1.1 ± 0.9, and hip BMD T-score was 0.5 ± 0.8 with nor-
mal ECG (resting and exercise) and carotid duplex ﬁndings
had been participated as control subjects.
All cases included in this study were subjected to the
following:
- Complete history taking and clinical examination with
special stress on cardiac symptoms, presence of cardiovas-
cular risk factors such as smoking, hypertension, dyslipi-
demia, family history of premature CAD. Body mass
index (BMI), duration of rheumatoid, menopausal history
(all females patients included in the study were on
perimenopausal stage i.e. irregular menses in the last
Figure 1 Coronary angiography showing signiﬁcant left coronary artery disease (narwoing and turtuosity).
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were under Methotrexate as a monotherapy disease mod-
ifying antirheumatic drugs {DMARDs}in a dose between
12.5 and 15 mg/week, and consuming non- steroidal anti
inﬂammatory drugs{NSAIDs} on irregular basis, stopped
corticosteroid therapy in last 5 years of the disease dura-
tion and on daily requirements of Calcium and Vitamin
D).
- Disease activity in RA patients was assessed by measuring
DAS-28 [17] and the Modiﬁed Health Assessment Ques-
tionnaire (MHAQ), a standard 8-question instrument,Figure 2 Coronary angiography showing signiﬁcwas used to assess functional capacity based on the difﬁ-
culty in performing activities of daily living [18].
- Laboratory investigations including serum lipid proﬁle,
ESR, CRP, serum blood glucose, kidney function tests
and BMD T-scores were documented from patient’s ﬁles
on their regular visits, while plasma TM and serum OPG
were measured.
- Resting and exercise ECG stress test.
- Coronary angiography in patients with positive results on
exercise ECG stress test.
- Carotid IMT measurement.ant right coronary artery disease (occlusion).
A.M. Alsalawy et al.2.1. Laboratory procedures
Venous blood samples were collected from patients and con-
trols under aseptic precautions, serum and citrated plasma
were prepared from the fasting blood sample, aliquoted and
stored at 20 C until further analysis.
2.2. Estimation of plasma TM
Plasma TM was quantiﬁed by ELISA technique using a two
site monoclonal enzyme immunosorbent assay for TM pro-
vided by Diagnostica Stago Asserachrom, Asmieres, France
as described in [19].
2.3. Determination of serum OPG
Serum OPG was measured by a commercially available kit
(R&D Systems, Minneapolis, MN, USA) as described in [20].
2.4. Exercise ECG stress test
Antihypertensive treatments with B-adrenergic blocking agents
together with food and beverages containing caffeine asked to
stop for at least 12 hours before the test. An exercise test was
performed according to the Bruce protocol using a Cardiocon-
trol treadmill [21].
2.5. Coronary angiography
In patientswith positive results on exercise ECGstress test, diag-
nostic coronary angiography was performed using the standard
Judkin’s technique on Philips catheter system and all images
were digitally stored in Dicom format on a Hewlett Packard
38Table 1 Clinical and laboratory ﬁndings of rheumatoid arthritis pa
Variables Rheumatoid without CAD (n= 2
Age (years) 52.43 ± 3.2
Sex (F/M) 16/4
Body mass index 27.2 ± 1.9
Smokers, n (%) 5 (25%)
Disease duration (years) 8.3 ± 2.2
Hypertensive n (%) 7 (35%)
Positive RF n (%) 16 (80%)
Positive ACPA n (%) 19 (95%)
Family history of CAD, n (%) 2 (10%)
Serum cholesterol (mg/dl) 235 ± 17
Serum triglycrides (mg/dl) 160 ± 20
Serum HDL-C (mg/dl) 35 ± 1.7
Serum LDL-C (mg/dl) 147 ± 24.5
ESR (mm/h) 40.80 ± 10.7
C-reactive protein (mg/L) 20.5 ± 10.7
BMD T-score
(i) Vertebral 1.8 ± 0.8
(ii) Hip 0.9 ± 0.9
MHAQ 2.25 ± 0.847
DAS28 4.35 ± 0.8
Rheumatoid factor (RF), Anti-citrullinated protein antibodies (ACPA), H
sedimentation rate (ESR), C reactive protein (CRP) and Bone mineral dvisualize work station for further analysis. A narrowing of >
50% in luminal diameter for one of the major epicardial coro-
nary arteries was considered hemodynamically signiﬁcant, and
the patient was classiﬁed as having CAD [21], .Figs. 1 and 2.
2.6. Carotid intima media thickness
Carotid duplex scanning was performed on all subjects who
participated in the study. Ultrasound examination was done
using a 7.5 MHz linear-phased array transducer and imaging
system of Hewlett Packard Sonos 5500. Right and left distal
common carotid arteries were examined following standard
procedures as in [22], values less than 0.8 mm correlate with
lack of CAD whereas an increasing thickness above was con-
sidered abnormal [22,23].
Statistics: Results were expressed as mean ± SD. Compar-
isons between groups were made using Student’s t-test for con-
tinuous variables. Correlation between the two parameters was
determined by Pearson’s correlation coefﬁcient (r). Odds ratios
(ORs) were estimated with corresponding 95% conﬁdence
intervals (CIs). P values < 0.01 were considered statistically
signiﬁcant.3. Results
The demographic, clinical and laboratory features of rheuma-
toid arthritis patients with and without CAD are presented in
Table 1. Group I included 16 females and 4 males, their mean
age was 52.4 ± 3.2 years, the mean duration of disease was
8.3 ± 2.2 years, their mean body mass was 27.2 ± 1.9, and
16 patients (80%) had rheumatoid factor (RF) positive (above
20 iu/ml) while 19 patients (95%) had anticitrullinated protein
antibodies (ACPA) positive. Group II included 17 females andtients without and with CAD.
0) Rheumatoid with CAD (n= 20) Control (n= 20)
51.1 ± 3.8 50.2 ± 3.3
17/3 14/6
29.6 ± 2.1 26 ± 1.6
14 (70%) 12(60%)
10.2 ± 4.2 –
12 (60%) 0 (0%)
18 (90%) –
20 (100%) –
4 (20%) 0 (0%)
267 ± 30 187 ± 12
180 ± 32 145 ± 24
33 ± 1.4 59 ± 90
170 ± 35 118 ± 29
40.75 ± 9.22 –
22.8 ± 9.7 –
1.7 ± 0.6 1.1 ± 0.9
1.1 ± 0.3 0.5 ± 0.8
2.38 ± 0.72
4.26 ± 0.63
igh density protein (HDL), Low density protein (LDL), Erythrocytes
ensity (BMD).
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of the disease is 10.2 ± 4.2 years, their mean body mass index
was 29.6 ± 2.1, and 18 patients (90%) had rheumatoid factor
(RF) positive(above 20 IU/ML) while all of them 20 patients
(100%) had anticitrullinated protein antibodies (ACPA)
positive.
Serum OPG level and plasma TM were signiﬁcantly higher
in RA patients with CAD than in those without CAD and con-
trols (P< 0.001), also OPG level in RA patients without CAD
as compared to controls (P< 0.01), however, there was no sig-
niﬁcant difference in plasma TM between patients without
CAD and controls as shown in Table 2. Carotid artery IMT
was signiﬁcantly increased in RA patients with and without
CAD as compared to controls (P< 0.01) (2) Table 3.
In RA patients without CAD, serum OPG correlated signif-
icantly with age (r= 0.69, P< 0.001), duration of disease
(r= 0.71, P= 0.001), carotid IMT (r= 0.65, P< 0.01),
DAS-28, ESR and CRP whereas there were no correlations be-
tween serum OPG and BMI, serum lipid proﬁle, plasma TM,
or MHAQ (3). In those with CAD, serum OPG correlated sig-
niﬁcantly with age, duration of rheumatoid, plasma TM, DAS-
28, ESR, CRP, MHAQ and carotid IMT (P< 0.001) but not
with BMI or serum lipid proﬁle (3).
Figs. 1 and 2 showed changes that occurred in left and right
coronaries in patients with CAD (group II) which ranged be-
tween narrowing and tortuosity as in Fig. 1, and complete
occlusion as in Fig. 2.
4. Discussion
Chronic inﬂammation plays an important role in pathogenesis
of atherosclerosis and RA. There is increasing evidence from
controlled clinical studies stating that there is a high incidence
of cardiovascular diseases in RA [24–26].
It has been documented that progression of atherosclerotic
calciﬁcation is inversely correlated with low bone tissue miner-
alization [27] and is associated with bone loss in older men [28]
and in postmenopausal women [29,30]. Jesper et al [27] docu-
mented that loss of bone mass in osteoporosis leads to in-
creased circulating phosphate and calcium and decreased
parathyroid hormone, which stimulate mineralization of car-
diovascular tissue, also pointed on the importance of cytokines
such as interlukin-1, and tumor necrosis factor in relationship
between osteoporosis and atherosclerosis. Experimental stud-
ies have suggested that OPG may work as an inhibitor of vas-Table 2 Comparison of serum OPG, plasma TM and carotid IMT
Serum OPG (pm
Controls (n= 20) 1.6 ± 1.2
Rheumatoid without CAD (n= 20) 3.1 ± 1.7
Rheumatoid with CAD (n= 20) 6.3 ± 2.8
P1 <0.01*
P2 <0.001*
P3 <0.001*
P1 rheumatoid without CAD vs. controls.
P2 rheumatoid with CAD vs. controls.
P3 rheumatoid with vs. without CAD.
* P< 0.01 signiﬁcant.cular calciﬁcations, as mice which were treated by fc OPG
showed a signiﬁcant reduction in calciﬁed area without affec-
tion of vascular cytokines [31] also parenteral administration
of OPG prevented vascular calciﬁcation induced by warfarin
and toxic doses of vitamin D in rats [32]. Thus, OPG is a cru-
cial tie between skeletal and vascular systems [8].
Importantly, OPG levels provide prognostic information in
patients who develop heart failure after acute myocardial
infarction (AMI) [33], so OPG might represent a novel marker
of plaque instability and cardiovascular mortality in these pa-
tients [34].
Since a strong association has been reported between OPG
and the presence and severity of CAD [35,36], this study was
designed to investigate the association of OPG serum levels
with the presence of asymptomatic CAD in patients with rheu-
matoid arthritis and to evaluate its relationship with plasma
TM as a marker of endothelial dysfunction and with carotid
IMT as a marker of atherosclerosis.
Serum levels of OPG were signiﬁcantly higher in RA pa-
tients with and without CAD compared to controls
(P< 0.001 and P< 0.01; respectively). There were also signif-
icant positive correlations between OPG serum levels and age,
duration of rheumatoid arthritis, ESR, CRP and DAS-28 in
patients with and without CAD however, no correlations were
found between serum OPG and BMI and any of lipid proﬁles.
Although the function of OPG in the vasculature is debat-
able, our results were compatible with the ﬁndings of Shopped
et al, [14] who described increased plasma concentrations of
OPG in men with CAD also with the results of work of Unna
M et al, [37] who could explain the important role of RANKL/
OPG system in pathogenesis of atherosclerosis in inﬂamma-
tory rheumatic diseases.
Solomon et al ,[38] demonstrated that several inﬂammatory
biomarkers linked to cardiovascular diseases (CVD) were sig-
niﬁcantly elevated in women with RA, including CRP, ﬁbrin-
ogen, serum intercellular adhesive molecules(sICAM-1),
soluble tumor necrosis factor receptor I and II (stoner I&II),
and OPG. The elevation of OPG in the context of RA has been
reported by previous published study which explained that
OPG is modulated by the immune system, and may act as a
counter-regulatory molecule that compensates for increased
production of RANK [25].
The positive associations between OPG concentrations and
ESR, CRP and duration and activity of RA observed by
Kubota et al [39] and Ziolkowska et al [15] who reported high-in patients and controls.
ol/l) Plasma TM Carotid IMT
(ng/ml) (mm)
37 ± 6.6 0.59 ± 0.19
42.1 ± 10.5 0.81 ± 0.23
77.8 ± 15.4 1.36 ± 0.28
>0.05 <0.01*
<0.001* <0.001*
<0.001* <0.001*
Table 3 Correlation between serum OPG (pmol/l) and other
parameters in rheumatoid with and without CAD.
Parameters Group I Group II
R P-value r P-value
Age (years) 0.69 <0.001 0.72 <0.001*
Body mass index 0.29 >0.05 0.34 >0.05
Disease duration (years) 0.71 <0.001* 0.74 <0.001*
Serum cholesterol (mg/dl) 0.21 >0.05 0.27 >0.05
Serum triglycerides (mg/dl) 0.35 >0.05 0.38 >0.05
Serum HDL-c (mg/dl) 0.25 >0.05 0.22 >0.05
Serum LDL-c (mg/dl) 0.41 >0.05 0.39 >0.05
Plasma TM (ng/dl) 0.36 >0.05 0.73 >0.001*
Carotid IMT (mm) 0.65 <0.01 0.84 <0.001*
ESR (mm/H) 0.69 <0.001* 0.79 <0.001*
CRP (mg/L) 0.76 <0.001 0.78 <0.001*
MHAQ 0.34 >0.05 0.64 <0.001*
DAS28 0.79 <0.001* 0.69 <0.001*
High density protein (HDL), low density protein (LDL), plasma
thrombomodulin (TM), carotid in time media thickness (IMT),
erythrocytes sedimentation rate (ESR), C reactive protein (CRP),
modiﬁed health assessment questionnaire (MHAQ), disease active
score 28 (DAS28).
* P< 0.001 signiﬁcant.
40 A.M. Alsalawy et al.er serum levels of OPG in RA patients ,and documented that
proinﬂammatory cytokines enhanced OPG production and
anti-TNF alpha treatment resulted in the normalization of ser-
um OPG levels in RA patients. In addition to its association
with inﬂammatory markers in RA, OPG is associated with
an increased burden of atherosclerosis.
The results of our study showed that carotid artery IMT
was increased in rheumatoid patients with and without CAD
as compared to controls (P< 0.001 and P< 0.01; respec-
tively) and serum OPG correlated signiﬁcantly with IMT in
rheumatoid patients with and without CAD (P< 0.001 and
P< 0.01; respectively). This ﬁnding is in agreement with
Kiechl et al. (2004) [20], who found that OPG was signiﬁcantly
and independently related to severity and 10-year progression
of carotid atherosclerosis. Golleedge et al. [40] reported also
increased concentrations of OPG within unstable (symptom-
atic) compared with stable (asymptomatic) carotid atheroscle-
rosis. Moreover, serum OPG level was positively correlated
with IMT of carotid arteries in healthy postmenopausal wo-
men [41] and also in end stage renal disease [42].
We also observed that serum OPG level was correlated with
plasma thrombomodulin (TM) a marker of endothelial dys-
function, only in rheumatoid patients with CAD, but not in
those without CAD as compared to controls. These ﬁndings
are correlated with Chung et al. [1] and Roman et al. [24]
who described in their studies that patients with RA have
accelerated atherosclerosis and their ﬁndings suggested that
serum OPG is a better and early predictor of atherosclerosis
in rheumatoid arthritis.
Although the precise biological role of OPG in vascular dis-
eases remains unclear, elevated serum levels of this vascular
protective factor could be interpreted as an insufﬁcient com-
pensatory self-defensive mechanism against factors that pro-
mote arterial calciﬁcation and atherosclerosis [43]. Therefore,
it could be assumed that raised OPG is a response to rather
than a cause of atherosclerosis, in an attempt to prevent fur-ther vascular damage which correlate with the ﬁndings of Sha-
ker et al, [2] who stated in their study that elevation of OPG
levels may represent a crucial compensatory mechanism to lim-
it further vascular damage. Moreover, Pedersen et al. [44] dem-
onstrated that elevated OPG levels are associated with
increased risk of acute events in stable angina pectoris patients,
though independent effects are restricted to a particular sub-
group with markedly enhanced activity in the OPG/
RANKL/RANK system, as reﬂected by high OPG levels.
However, at high concentrations, OPG can also enhance the
matrix metalloproteinase (MMP)-inducing effect of RANKL
as well as having metalloproteinase (MMP)-inducing and che-
mo tactic effects of its own [45,46]. Serum OPG level therefore
may reﬂect inﬂammation and matrix degradation as well as
vascular calciﬁcation.
Thus, therapeutic strategies aimed at increasing local OPG
concentrations in bone and the vascular wall using gene ther-
apy with human recombinant OPG, might be protective
against osteoporosis and atherosclerosis [47].
By investigating OPG and other bone-related molecules in
relation to the arterial wall, we would gain a new perspective on
the understanding of the molecular mechanisms underlying the
development of macrovascular disease in rheumatoid arthritis.
In conclusion, from this study, it could be concluded that
osteoprotegerin is a clinically important molecule, indepen-
dently associated with the presence of coronary artery disease
and may be a good indicator of atherosclerotic vascular dam-
age (macroangiopathy) in rheumatoid arthritis. Hence, mea-
surement of serum OPG merits further investigation as a
simple test for improving early diagnosis of asymptomatic
CAD in rheumatoid arthritis patients. Further larger, prospec-
tive studies are required to clarify the causative relation be-
tween OPG, rheumatoid arthritis and atherosclerotic
vascular disease as well as clinical trials of novel agents for cor-
recting causal mechanisms and to evaluate a possible therapeu-
tic potential of OPG as a new ‘‘vasculoprotegerin’’.
Future research on OPG gene polymorphisms could play a
role in the development, progression and response to therapy
in rheumatoid vascular complications.References
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